Clostridium Difficile News and Research

RSS

Clostridium difficile is a type of bacterium found in human and animal waste. Clostridium difficile is a common cause of diarrhea that occurs in hospitals. It can also cause diarrhea or other intestinal disorders in patients treated with antibiotics.

FDA accepts Optimer's fidaxomicin NDA for filing

Optimer Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for reducing the risk of recurrence when used for treatment of initial CDI.

24 Jan 2011

IMDx enters multi-year agreement with Abbott Molecular for m2000 instrument system

IMDx today announced that they have signed a multi-year agreement with Abbott whereby IMDx will design, develop, regulatory clear, and manufacture assays for the Abbott Molecular FDA cleared, m2000 instrument system to be distributed worldwide. Financial terms have not been disclosed.

21 Jan 2011

UMMS begins MBL-HCV1 Phase 2 trial to prevent hepatitis C virus infection in liver transplant patients

Following a successful Phase 1 study for safety, researchers at MassBiologics of the University of Massachusetts Medical School today announced the beginning of a Phase 2 clinical trial testing the ability of a human monoclonal antibody they developed to prevent hepatitis C virus infection of a donor liver in transplant patients.

19 Jan 2011

Clostridium bacteria may offer a greener alternative to petrol

A diverse family of bacteria that can cause a potentially fatal illness in humans but could offer a greener alternative to petrol to power our cars will be the subject of a talk by a University of Nottingham academic at an international conference.

12 Jan 2011

IDSA releases MRSA treatment guidelines

Physicians now have help in their battle against methicillin resistant Staphylococcus aureus (MRSA), a potentially deadly infection that initially was limited to hospitals and health care facilities but has become a growing problem in healthy children and adults. The Infectious Diseases Society of America (IDSA) has released its first guidelines for the treatment of increasingly common MRSA infections.

7 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

C. difficile infection has become common among hospitalized children in the US

Hospitalized children in the United States are more frequently becoming infected with the bacteria Clostridium difficile, according to a report posted online today that will appear in the May print issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

3 Jan 2011

Tru-D UV-C device effective in reducing pathogens on all environmental surfaces in hospital patient rooms

Results of an eight-month hospital study, "Room Decontamination with UV Radiation," were published in the October 2010 issue of "Infection Control and Hospital Epidemiology." The study evaluated the ability of an automated UV device, Tru-D, to decontaminate patient rooms contaminated with MRSA, VRE, C. difficile and a MDR strain of Acinetobacter baumannii.

10 Dec 2010

Scientists determine 500 three-dimensional protein structures from bacterial and protozoan pathogens

9 Dec 2010

Scientists work together to wipe out some of the most lethal diseases

Scientists at Seattle Biomedical Research Institute and Northwestern University Feinberg School of Medicine have reached a major milestone in the effort to wipe out some of the most lethal diseases on the planet. As leaders of two large structural genomics centers, they've experimentally determined 500 three-dimensional protein structures from a number of bacterial and protozoan pathogens, which could potentially lead to new drugs, vaccines and diagnostics to combat deadly infectious diseases.

8 Dec 2010

Idis to manage ViroPharma's named patient program

ViroPharma Incorporated and Idis, the global leader in developing long-term strategic solutions to therapeutic access, today announced that the two companies have partnered to facilitate access to certain ViroPharma products through a named patient program (NPP). ViroPharma's NPP, developed and managed by Idis, will allow international healthcare professionals to prescribe certain products to individual patients until the time that approval is sought in local countries.

7 Dec 2010

Sanofi Pasteur commences phase II clinical study of vaccine for Clostridium difficile infection prevention

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has started its phase II clinical study of a vaccine for primary prevention of Clostridium difficile infection (CDI). The trial starting in the United States is focused on evaluating prevention of the first episode of CDI in at-risk individuals, which includes adults with imminent hospitalization or current or impending residence in a long-term care or rehabilitation facility.

30 Nov 2010

National campaign to highlight significance of antibiotic resistance

Antibiotic resistance is one of the world's most pressing public health threats. To bring attention to this increasing problem, the Centers for Disease Control and Prevention and other government partners will observe its third annual Get Smart About Antibiotics Week on Nov. 15-21, 2010.

16 Nov 2010

ViroPharma presents data on Cinryze C1 esterase inhibitor for HAE at ACAAI Meeting

ViroPharma Incorporated today announced data in four poster presentations and two oral presentations relating to Cinryze (C1 esterase inhibitor [human]) at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), November 11 through 16 in Phoenix, Ariz.

16 Nov 2010

Novel light technology kills hospital superbugs

A pioneering lighting system that can kill hospital superbugs - including MRSA and C.diff - has been developed by researchers at the University of Strathclyde in Glasgow. Scotland.

15 Nov 2010

PenCLAHRC provides funding to support C. difficile research

The Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) has provided funding to support joint research between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust to investigate why some cases of Clostridium difficile infection (CDI) are more difficult to treat than others and also why some cases result in more incidences of relapses.

12 Nov 2010

PPH uses Xenex PX-UV disinfection system to destroy microorganisms causing HAIs

Palomar Pomerado Health (PPH) today announced it is the first health system in California to use the Xenex PX-UV disinfection system in its patient and operating rooms. The Xenex system is the fastest, safest and most cost-effective method for the advanced cleaning of hospital rooms in the world today, scientifically proven to destroy all major classes of microorganisms that cause hospital acquired infections (HAIs), such as MRSA and Clostridium difficile (C. diff).

11 Nov 2010

Intercell aggregate revenues decrease 28.4% to EUR 21.1m in 9 months ended September 30, 2010

Today, Intercell AG announced its financial results for the third quarter of 2010 and presented an update on the Company's key R&D programs as well as changes to the Management Board.

9 Nov 2010

Optimer third quarter net loss increases to $11.8 million

Optimer Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2010. Optimer reported a net loss for the third quarter of 2010 of $11.8 million, or $0.30 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share. The increase in net loss was primarily due to an increase in research and development and marketing expenses.

2 Nov 2010

H. pylori infection reduces severity of Salmonella-induced colitis: Research

Helicobacter pylori, a common stomach bacterium, reduced the severity of inflammation of the colon caused by Salmonella in mice, according to research from U-M Medical School scientists.